← العودة إلى الصفحة الرئيسية
آسيا · الأسواق الإقليمية · Yicai Global

China Adds Biogen’s USD210,000 Innovative ALS Drug to Commercial Insurance List

نشره Yicai Global · الصين منذ 12 س
China Adds Biogen’s USD210,000 Innovative ALS Drug to Commercial Insurance List
China Adds Biogen’s USD210,000 Innovative ALS Drug to Commercial Insurance List · Yicai Global

ملخص مفصل

(Yicai) Nov. 16 -- China’s National Healthcare Security Administration has included Tofersen, the world’s first drug for amyotrophic lateral sclerosis caused by SOD1 gene…

(Yicai) Nov. 16 -- China’s National Healthcare Security Administration has included Tofersen, the world’s first drug for amyotrophic lateral sclerosis caused by SOD1 gene mutations, developed by US pharmaceutical giant Biogen, on its innovative medicine list for commercial insurance coverage.

Approved by the National Medical Products Administration in September 2024, Tofersen hit the Chinese market in June 2025, priced at CNY1.4 million (USD209,870) per year. It was added to the commercial insurance list on Nov. 14.

Tofersen’s distribution network in China now covers 18 provinces, according to the latest figures Biogen provided to Yicai. Although the drug has gained access to 17 Huiminbao special drug lists, there is still considerable room for expansion, given that more than 200 Huiminbao products remain in operation nationwide.

Huiminbao is a low-cost inclusive supplementary medical insurance program guided by local governments and financial regulators, underwritten by commercial insurers on a market basis. It is linked to China’s basic medical insurance system.

China has more than 1,000 patients with SOD1 mutation ALS, but only about 100 have received treatment, mainly because the drugs are not widely available in hospitals and most patients cannot afford them anyways, said Fan Dongsheng, director of neurology at Peking University Third Hospital and one of China’s leading experts in ALS clinical research and treatment.

Xia Sheng, an ALS patient in his 50s who has been receiving Tofersen for more than a year, told Yicai that thanks to an assistance program run by the Beijing Kangmeng Charity Foundation, his out-of-pocket cost was just over CNY700,000 (USD104,930) in the first year and more than CNY400,000 in the second year.

If commercial health insurance gradually provides additional coverage, costs are expected to further decline. However, pure commercial medical insurance products covering rare diseases remain extremely rare, and reimbursement under critical illness…

مطلع المقال، مقتطف من Yicai Global. لقراءة المقال كاملًا، افتحه على موقع الناشر.

اقرأ المقال كاملًا على Yicai Global سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.yicaiglobal.com)

يستحق القراءة أيضًا